Notably, HER2-CXCR5-CCR6-CAR T cells demonstrated significantly enhanced tumor infiltration compared to conventional HER2-CAR T cells, attributable to their triple-targeting capacity for tumor sites co-expressing HER2, CXCL13, and CCL20. The gene discussed is CCL20; the disease is neoplasm.